StockData
Beta Bionics, Inc. logo

Beta Bionics, Inc. (BBNX) company profile

BBNXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 11/304% below fair value
$14.72−0.49 (-3.22%)

Close on Nov 17, 2026Market cap $800.28MP/E –Yield –

About Beta Bionics

Surgical & Medical Instruments & Apparatus, SIC 3841

Beta Bionics, Inc. is a medical technology company that develops and commercializes automated insulin delivery solutions for diabetes management. The company's primary commercial offering is the iLet, an automated insulin dosing system, alongside related single-use products and components. Its technology is designed for patients with type 1 diabetes, specifically cleared for adults and children aged six and older. The company distributes its medical devices and supplies to patients through healthcare channels, including durable medical equipment providers and pharmacy benefit plans.

The company conducts its commercial operations in the United States, where its primary device has received regulatory clearance. It maintains business relationships with multiple distributors across domestic channels to distribute its systems and consumable supplies. Beta Bionics is incorporated in Delaware and maintains its principal executive offices and corporate headquarters in Irvine, California.

Summary of the business section of Beta Bionics's latest annual report, written by StockData.

Company profile

Company

Legal name
Beta Bionics, Inc.
Headquarters
Irvine, CA
Address
11 Hughes 92618
Phone
(949) 427-7785
Employees
420, Dec 31, 2025
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, San Diego, California

Stock & identifiers

Ticker
BBNX
Exchange
Nasdaq
IPO date
Jan 31, 2025
Shares outstanding
54M, Oct 26, 2026
Public float
$632.00M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
1674632
CUSIP
08659B102
ISIN
US08659B1026
FIGI
BBG00JNGG9Q2
Share class FIGI
BBG00JNGG9R1
EIN
47-5386878

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Sean SaintPresident & CEO, Director398,429
Stephen FeiderChief Financial Officer159,378
Mark HopmanChief Commercial Officer54,143
Mike MensingerChief Product Officer174,740
Steven Jon RussellChief Medical Officer207,699
Christy JonesDirector19,564
Danny L. DearenDirector32,209
Sean CarneyDirector32,209
Gerard J. MichelDirector33,509
Maria PalasisDirector29,397
Adam LezackDirector27,399

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Sean Saint
President and Chief Executive Officer
$700.00K$1.58M$8.98M$894.60K$31.00K$12.19M+1277%
Stephen Feider
Chief Financial Officer
$475.00K$689.49K$3.68M$333.88K$23.50K$5.20M+688%
Mike Mensinger
Chief Product Officer (5)
$450.00K$513.45K$2.34M$316.31K$23.25K$3.64M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jan 31, 2025
Offer price
$17.00
Securities offered
12,000,000
Gross proceeds
$204.00M
Exchange
Nasdaq
First trading day
Jan 30, 2025
First-day close
$23.63+39.0%
Lock-up ends (est.)
Jul 29, 2025

“Per Share Total Initial public offering price $ 17.00 $ 204,000,000 Underwriting discounts and commissions (1) $ 1.19 $ 14,280,000 Proceeds, before expenses, to Beta Bionics, Inc.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 420 full-time employees and three part-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?